As one illustration of the use of Weibull parameterization, we analyzed a recent trial that encompassed both Phase 1 and 2 data and tested pembrolizumab with dabrafenib and trametinib for metastatic BRAF-mutant melanoma (MK-3475-022/KEYNOTE-022; NCT02130466)40. This evidence concerns the gene BRAF and melanoma.